Table 4.

KEYNOTE-024 study: clinical outcomes of pembrolizumab versus first-line chemotherapy.

Total population (TPS ⩾ 50%)	Pembro 200 mg n = 154	First-line chemotherapy n = 151	p
mPFS (95% CI), months	10.3 (6.7–NR)	6.0 (4.2–6.2)	<0.001
HR (95% CI)	0.50 (0.37–0.68)
mOS (95% CI), months	NR	NR	0.005
HR (95% CI)	0.60 (0.41–0.89)
6-month OS rate (%) (95% CI)	80.2 (72.9–85.7)	72.4 (64.5–78.9)
ORR, % (95% CI)	44.8 (36.8–53.0)	27.8 (20.8–35.7)
mDOR (range), months	NR (1.9+ to 14.5+)	6.3 (2.1+ to 12.6+)

+, ongoing response; CI, confidence interval; HR, hazard ratio; mDOR, median duration of response; mOS, median overall survival; mPFS, median progression-free survival; NR, not reached; ORR, objective response rate; Pembro, pembrolizumab; TPS, tumor proportion score.